TURNOVER (x1000 SEK)
NET PROFIT (x1000 SEK)
EMPLOYEES
ImmunoIVD AB
Closing information (x1000 SEK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
58,270
|
49,234
|
42,371 |
| Financial expenses |
1,518
|
1,688
|
1,581 |
| Earnings before taxes |
13,402
|
4,406
|
5,560 |
| EBITDA |
16,650
|
8,024
|
9,576 |
| Total assets |
42,539
|
32,893
|
31,240 |
| Current assets |
36,532
|
26,665
|
25,077 |
| Current liabilities |
24,543
|
24,824
|
24,129 |
| Equity capital |
17,996
|
8,069
|
7,111 |
| - share capital |
100
|
100
|
100 |
| Employees (average) |
27
|
25
|
23 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
42.3%
|
24.5%
|
22.8% |
| Turnover per employee |
2,158
|
1,969
|
1,842 |
| Profit as a percentage of turnover |
23.0%
|
8.9%
|
13.1% |
| Return on assets (ROA) |
35.1%
|
18.5%
|
22.9% |
| Current ratio |
148.8%
|
107.4%
|
103.9% |
| Return on equity (ROE) |
74.5%
|
54.6%
|
78.2% |
| Change turnover |
9,036
|
6,863
|
7,063 |
| Change turnover % |
18%
|
16%
|
20% |
| Chg. No. of employees |
2
|
2
|
-3 |
| Chg. No. of employees % |
8%
|
9%
|
-12% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.